The first US patient has been dosed with an investigational stem cell therapy called IMS001, for multiple sclerosis (MS), developed by ImStem Biotechnology.
ImStem Biotechnology’s Drs. Xiaofang Wang and Ren-He Xu were awarded $1.1 million in state stem cell funding.
“ImStem's work is not only important from a public health standpoint, but is part of a wider growing biotech industry that is creating well-paying, high-tech jobs,” said Mike Demicco (D-Farmington).
The FDA has lifted the clinical hold and cleared the investigational new drug (IND) application to assess IMS001 in the treatment of multiple sclerosis (MS).